Foscelantan wound plate for infected diabetic foot or vein-related wounds
Compares Foscelantan with povidone-iodine for infected diabetic or venous wounds.
Key facts
- Who runs it
- Research Institute for Physical Chemical Problems of the Belarusian State University
- Where
- Belarus2 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Clinical Study in Adult Patients With Purulent-inflammatory Processes of the Skin and Soft Tissues, Phase I-II of the Wound Process
- Status
- Not yet recruiting
- Phase
- Phase 2/3
- People taking part
- 224 people, planned
- Started
- Nov 2025
- Planned end
- May 2026
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Foscelantan
- Povidon-iodine
- Record updated
- 25 July 2025
Who can take part
The trial is looking for adults with infected, inflamed skin wounds (ulcers). The wounds must be caused by the neuropathic form of diabetic foot or by chronic venous insufficiency (varicose veins of the legs), in the early phases (I-II) of wound healing.
- Age
- 18 to 70 years
- Sex
- All sexes
- Disease stage
- Diabetic foot: diabetes type I or II that is controlled or partly controlled, Wagner class I - II. Venous disease: CEAP class C6. Wound size from 1 cm² to 20 cm². No bone or tendon showing in the wound. The wound heals by secondary healing, meaning it is left open to heal.
- Earlier treatment
- People who need steroid therapy cannot join. People who must keep taking drugs on the protocol's list of banned treatments cannot join.
- Biomarker or test result
- White blood cells must not be below 1.5 × 109 per l, platelets not below 75.0 × 109 per l, and hemoglobin not below 80g per l.
- Main reasons for not taking part
- Neuroischemic form of diabetic foot (nerve damage plus poor blood flow), or diabetes that is out of control
- Serious other illness such as severe kidney, liver or heart failure, cancer, or mental illness
- Positive test for syphilis, HIV, hepatitis B or hepatitis C
- Allergy to parts of Foscelantan, or acute bleeding
- Pregnancy or breastfeeding, or another clinical trial in the past 3 months
Show the full registry criteria (24)Hide the full registry criteria
Who can take part
- The presence of purulent-inflammatory processes of the skin and soft tissues due to the neuropathic form of diabetic foot syndrome (Main diagnosis: Diabetes mellitus type I or II, clinical metabolic compensation/subcompensation, class I - II according to the Wagner classification) or chronic venous insufficiency (Main diagnosis: Varicose veins dilatation of the veins of the lower extremities, class C6 according to the CEAP classification), phase I-II of the wound process
- The size of the ulcerative defect is from 1 cm² to 20 cm²
- Secondary type of wound healing
- Absence of exposed bones and tendons in the wound
- Absence of severe concomitant diseases in the stage of decompensation, oncological diseases, as well as diseases requiring steroid therapy
- Availability of written informed consent from the patient to participate in the study
- The patient's ability to follow the instructions of the research physician and comply with the study regimen
Who cannot take part
- The presence of serious concomitant pathology (severe form of renal and hepatic failure, systemic connective tissue diseases, severe cardiovascular insufficiency), history and current mental illness
- The need to constantly take drugs from the list of prohibited therapies
- Participation of the patient in another clinical trial within 3 months before the current clinical trial
- At the request of the research physician, if the research subject violates the protocol requirements for diet, consumption of alcoholic beverages, and medications without the prescription of the research physician
- For reasons independent of the study subject and the research physician, when a study subject develops drug intolerance and other life-threatening or requiring emergency pharmacotherapy adverse reactions to the administration of the study drug
- The need to prescribe drugs from the list of prohibited treatments
- Individual intolerance or hypersensitivity reactions to the components of the drug Foscelantan
- Neuroischemic form of diabetic foot syndrome
- Acute bleeding
- Positive tests for syphilis, human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
- Diabetes mellitus in a state of clinical and metabolic decompensation
- Level of peripheral blood leukocytes less than 1.5 × 109 per l, platelets less than 75.0 × 109 per l
- Hemoglobin less than 80g per l
- Severe liver dysfunction - AST or ALT levels exceed the upper limit of normal by 5 times or more, bilirubin ≥ 2.0 mg/dL (34.2 µmol/L)
- Severe renal dysfunction - creatinine 2 times higher than reference values
- Pregnant and breastfeeding women
- At one\'s own request without explaining the reasons for the action
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Diabetic foot infections or chronic venous insufficiency
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to estimate efficiency, tolerance, safety of "Foscelantan, medicinal plate 4.0x5.0 cm in package No. 1" among adult patients who have purulent-inflammatory processes of the skin and soft tissues due to the neuropathic form of diabetic foot syndrome or chronic venous insufficiency, phase I-II of the wound process.
The 4 groups in the trial
- Patients with the neuropathic form. Treatment with FoscelantanTreatment being tested
A prospective, parallel, single-blind clinical study using stratified randomization of the effectiveness, tolerability and safety of the drug "Foscelantan, medicinal plate 4.0×5.0 cm in package No. 1" produced by UNITEHPROM BSU, Republic of Belarusin adult patients with purulent-inflammatory processes of the skin and soft tissues due to the neuropathic form of diabetic foot syndrome, phase I-II wound process. All patients will receive systemic traditional therapy for the underlying and concomitant diseases.
Treatment: Foscelantan
- Patients with the neuropathic form. Treatment with Povidone-iodineExisting treatment, for comparison
A prospective, parallel, single-blind clinical study using stratified randomization of the effectiveness, tolerability and safety of the drug Povidone-iodine produced by BelAseptika JSC, in adult patients with purulent-inflammatory processes of the skin and soft tissues due to the neuropathic form of diabetic foot syndrome, phase I-II wound process. All patients will receive systemic traditional therapy for the underlying and concomitant diseases.
Treatment: Povidon-iodine
- Patients with chronic venous insufficiency. Treatment with FoscelantanTreatment being tested
A prospective, parallel, single-blind clinical study using stratified randomization of the effectiveness, tolerability and safety of the drug "Foscelantan, medicinal plate 4.0×5.0 cm in package No. 1" produced by UNITEHPROM BSU, Republic of Belarus in adult patients with purulent inflammatory processes of the skin and soft tissues due to chronic venous insufficiency," phase I-II of the wound process. All patients will receive systemic traditional therapy for the underlying and concomitant diseases.
Treatment: Foscelantan
- Patients with chronic venous insufficiency. Treatment with Povidone-iodineExisting treatment, for comparison
A prospective, parallel, single-blind clinical study using stratified randomization of the effectiveness, tolerability and safety of the drug Povidone-iodine produced by BelAseptika JSC, in adult patients with purulent-inflammatory processes of the skin and soft tissues due to chronic venous insufficiency\", phase I-II of the wound process . All patients will receive systemic traditional therapy for the underlying and concomitant diseases.
Treatment: Povidon-iodine
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Parallel, Single-blind Clinical Study Using Stratified Randomization of the Effectiveness, Tolerability and Safety of the Medicinal Product "Foscelantan, Medicinal Plate 4.0x5.0 cm in Package No. 1" Produced by UNITEKHPROM BSU, Republic of Belarus, in Comparison With the Medicinal Product Povidone- Iodine Produced by BelAseptika JSC, in Adult Patients With Purulent-inflammatory Processes of the Skin and Soft Tissues Due to the Neuropathic Form of Diabetic Foot Syndrome or Chronic Venous Insufficiency, Phase I-II of the Wound Process
- Plain-language title
- Foscelantan wound plate for infected diabetic foot or vein-related woundsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT06232421, who can take part
- Record updated
- 25 July 2025